scholarly journals Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma

2012 ◽  
Vol 5 (1) ◽  
pp. 53-56 ◽  
Author(s):  
AKIRA KOMIYA ◽  
KENJI YASUDA ◽  
TETSUO NOZAKI ◽  
YASUYOSHI FUJIUCHI ◽  
SHIN-ICHI HAYASHI ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Dose Rate ◽  
Small Cell Carcinoma ◽  
High Dose Rate ◽  
Small Cell ◽  
Prostatic Adenocarcinoma ◽  
Low Risk ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Carcinoma Of The Prostate

scholarly journals Combined interstitial and surface high-dose-rate brachytherapy treatment of squamous cell carcinoma of the hand

2020 ◽  
Vol 12 (1) ◽  
pp. 48-52
Author(s):  
Daniel Kim ◽  
Ivan M. Buzurovic ◽  
Brandon Mahal ◽  
William Hwang ◽  
Oluwadamilola Oladeru ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Dose Rate ◽  
Squamous Cell ◽  
High Dose Rate ◽  
High Dose ◽  
High Dose Rate Brachytherapy

scholarly journals Small cell carcinoma of the prostate after low-dose-rate brachytherapy: a case report

2020 ◽  
Vol 14 (1) ◽  
Author(s):  
Eva Van Bos ◽  
Peter Dekuyper ◽  
Charlotte Gabriel ◽  
Marjan Waterloos ◽  
Anthony Van Baelen ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Dose Rate ◽  
Small Cell Carcinoma ◽  
Metastatic Disease ◽  
Low Dose ◽  
Specific Antigen ◽  
Small Cell ◽  
Carcinoma Of The Prostate ◽  
Low Dose Rate ◽  
Low Dose Rate Brachytherapy

Abstract Background Small cell carcinoma of the prostate is a rare condition with important differences from prostatic adenocarcinoma in terms of clinical and prognostic characteristics. A low prostate-specific antigen and a symptomatic patient, including paraneoplastic symptoms, characterize small cell carcinoma of the prostate. Diagnosis is made on the basis of prostate biopsy, and fluorodeoxyglucose positron emission tomography/computed tomography is often used for staging because up to 60% of patients present with de novo metastatic disease. Patients with metastatic disease are usually treated with platinum-based cytotoxic chemotherapy regimens similar to those used for small cell carcinoma of the lung. However, prognosis remains poor, with a median overall survival of 9 to 17 months despite therapy. Case presentation This report describes a case of an 80-year-old Caucasian patient with lymph node and bone metastatic small cell carcinoma of the prostate following low-dose-rate brachytherapy for a low-risk prostate carcinoma and treated with chemotherapy and immunotherapy. Conclusion Low-dose-rate brachytherapy might be an etiology of small cell prostate cancer.

scholarly journals High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer

2015 ◽  
Vol 1 ◽  
pp. 10-16 ◽  
Author(s):  
Ricardo Cendales ◽  
Elizabeth Alwers ◽  
Javier Cifuentes ◽  
Ivan Bobadilla ◽  
Felipe Torres ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
High Dose Rate ◽  
Low Risk ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Risk Prostate Cancer ◽  
Low Risk Prostate Cancer

High-Dose-Rate Brachytherapy in the Treatment of Carcinoma of the Prostate

2001 ◽  
Vol 8 (6) ◽  
pp. 511-521 ◽  
Author(s):  
A.M. Nisar Syed ◽  
Ajmel Puthawala ◽  
Anil Sharma ◽  
Sherief Gamie ◽  
Adina Londrc ◽  
...  
Keyword(s):  
Dose Rate ◽  
High Dose Rate ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Carcinoma Of The Prostate

Interstitial high-dose rate brachytherapy with iridium-192 in patients with oral squamous cell carcinoma

1995 ◽  
Vol 23 (4) ◽  
pp. 238-242 ◽  
Author(s):  
Reinhard E. Friedrich ◽  
Andreas Krüll ◽  
Dieter Hellner ◽  
Rudolf Schwarz ◽  
Daniel Heyer ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Dose Rate ◽  
Squamous Cell ◽  
High Dose Rate ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Iridium 192
Sign in / Sign up

Export Citation Format

Share Document